<DOC>
	<DOCNO>NCT00580788</DOCNO>
	<brief_summary>This dose escalation study determine maximum tolerable dose Parathyroid Hormone-related Protein , PTHrP , give safely one week . The investigator plan infuse low dos intravenous PTHrP determine lead sustain progressive suppression bone formation occur humoral hypercalcemia malignancy ( HHM ) increase bone formation occur hyperparathyroidism ( HPT ) . Additionally , investigator assess direct influence PTHrp marker bone turnover , plasma 1,25 ( OH ) 2 vitamin D regulation healthy human volunteer .</brief_summary>
	<brief_title>One Week Parathyroid Hormone-related Protein ( PTHrP ) IV Dose Escalation Study</brief_title>
	<detailed_description>During research investigator administer PTHrP healthy young volunteer control , continuous intravenous manner . As research subject complete week-long study without adverse effect , dose PThrP increase later subject . In event significant adverse effect , immediate action take reverse . The investigator want estimate effect sustainable level mild hypercalcemia achieve week-long intravenous infusion PTHrP vitamin D metabolism , marker bone turnover fractional excretion calcium .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Paraneoplastic Syndromes</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Healthy caucasian subject sex age 2435 year , able spend one week Clinical &amp; Translational Research Center University Pittsburgh Medical Center ( UPMC ) Montefiore Pregnancy Any cardiac , renal , pulmonary , endocrine , musculoskeletal , hepatic , hematological , malignant rheumatologic disease Body mass index great 30 Anemia Significant alcohol drug abuse Baseline hypotension hypertension Abnormal screening lab Use certain chronic medication exclude oral contraceptive Receiving investigational drug last 90 day Previously receive PTH PTHrP AfricanAmerican race</criteria>
	<gender>All</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>MusculoSkeletal System Diseases</keyword>
	<keyword>Hormones</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Postmenopausal Women</keyword>
	<keyword>Bone metabolism</keyword>
</DOC>